Form 4: Jazz Pharma Director's Stock Transactions

Jazz Pharmaceuticals plc Director Anne O'Riordan reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Summary

• Director Anne O'Riordan acquired 3,507 ordinary shares of Jazz Pharmaceuticals plc on August 7, 2025, through a grant of restricted stock units (RSUs) at a price of $0.0.
• These RSUs were granted under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and are scheduled to vest in full on July 24, 2026, subject to continuous service.
• On August 8, 2025, O'Riordan disposed of 1,805 ordinary shares at a price of $111.2494 per share.
• This sale was conducted to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, Anne O'Riordan beneficially owns 16,500 ordinary shares directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The RSU grant is a positive for aligning interests, while the sale is a routine tax-related event, not indicative of negative sentiment from the insider.

Positives

• Grant of 3,507 restricted stock units to a director, aligning management incentives with shareholder interests.
• The RSU grant is part of a pre-existing, approved stock award plan (2007 Amended and Restated Non-Employee Directors Stock Award Plan).

Negatives

• Sale of 1,805 shares, although for tax purposes, reduces the director's direct ownership.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector.

Comparison to Industry Standards

• This is a standard Form 4 filing detailing director compensation and tax-related share sales. Such transactions are common across publicly traded companies and do not lend themselves to direct comparison with specific company projects or results.
• The RSU grant and subsequent tax-related sale are typical mechanisms for director compensation and tax management in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, while the tax-related sale is a minor, routine event with minimal impact on overall share structure.

Next Steps

• The 3,507 restricted stock units granted on August 7, 2025, are scheduled to vest in full on July 24, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (RSU grant and tax-related sale) by a director. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal any significant positive or negative developments for the company's stock.

Keywords

Jazz Pharmaceuticals, JAZZ, SEC Form 4, insider trading, stock transactions, restricted stock units, RSU, director compensation, share sale, tax obligations